News

Lonza Group Ltd (LONN) Gets a Buy from Barclays
In a report released today, Charles Pitman CFA from Barclays maintained a Buy rating on Lonza Group Ltd (LONN – Research Report), with a price ...
Lonza price target lowered to CHF 670 from CHF 710 at Barclays
Barclays analyst Charles Pitman lowered the firm’s price target on Lonza (LZAGY) to CHF 670 from CHF 710 and keeps an Overweight rating on the ...
Lonza: Well Equipped In The U.S., Buy Confirmed
Lonza is poised for growth amid margin recovery, onshoring opportunities, and strong profit projections. Read more on LZAGY ...
Forbes6mon
Lonza Group
Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Pharma & Biotech; Specialty Ingredients; and Corporate.
Contract Pharma3d
Lonza Joins Center for Continuous Manufacturing and Advanced Crystallization
Lonza will serve as a CMAC Translation to Industry Collaborator, reinforcing its commitment to advancing innovative ...
Some May Be Optimistic About Lonza Group's (VTX:LONN) Earnings
SWX:LONN Earnings and Revenue History April 11th 2025 How Do Unusual Items Influence Profit? To properly understand Lonza Group's profit results, we need to consider the CHF284m e ...
Zacks Investment Research on MSN9d
Lonza Group (LZAGY) Upgraded to Buy: Here's What You Should Know
Lonza Group Ag (LZAGY) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of ...